Skip to main content
main-content

Latest news

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by


Type 1 diabetes

CGM use during pregnancy improves maternal glycemic control, neonatal outcomes

CGM

The CONCEPTT trial results suggest that the use of continuous glucose monitoring by pregnant women with type 1 diabetes improves glycemic control and neonatal outcomes relative to standard glucose monitoring.

Latest headlines

09-19-2017 | Diabetes distress | EASD 2017 | News

News in brief

Identifying diabetes distress may help direct healthcare resources

Researchers find that routinely asking patients with type 1 diabetes to complete the Diabetes Distress Scale-2 may direct more healthcare resources to those who need them and help to improve outcomes.

09-19-2017 | Cardiovascular outcomes | EASD 2017 | News

News in brief

Simple wellbeing query predicts MACE in type 2 diabetes

Asking two simple questions about the vitality and energy of patients with type 2 diabetes may help healthcare providers to predict their risk for major adverse cardiovascular events.

09-19-2017 | Genetics | EASD 2017 | News

Genetics point way to type 1 and monogenic diagnosis and prediction

Studies presented in a session on the genetics of diabetes, at the EASD annual meeting in Lisbon, Portugal, demonstrated the heterogeneity of type 1 diabetes risk and the predictive and diagnostic power of a genetic risk score.

Source:

EASD 2017; Lisbon, Portugal: 11–15 September

09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

Source:

Lancet Diabetes Endocrinol 2017; Advance online publication

In depth

SGLT2 inhibitors: The story so far

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class.

Dissecting the CANVAS trial

Listen to Editorial Board members and CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials.

Conference coverage

medwireNews attends conferences around the world, bringing you symposia highlights, breaking research news, and expert interviews. Click here to see our coverage so far.

image credits